UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
 
 
 
 
 
FORM 8-K
 
 
 
 
 
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
Date of report (Date of earliest event reported): November 1, 2016
 
 
 
 
 
 
  GALENA BIOPHARMA, INC.
(Exact name of registrant as specified in its charter)
 
 
 
 
 
Delaware
 
001-33958
 
20-8099512
(State or other jurisdiction of incorporation or organization)
 
(Commission
File Number)

 
(I.R.S. Employer
Identification No.)
 
 
 
 
 
 
 
2000 Crow Canyon Place, Suite 380, San Ramon, CA 94583
 
 
 
 
(Address of Principal Executive Offices) (Zip Code)

 
 
 
 
 
 
 
Registrant’s telephone number, including area code: (855) 855-4253

 
 
 
 
 


Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
o
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))







Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
(c) Appointment of Chief Financial Officer.
On November 3, 2016, Galena Biopharma, Inc. (“Company”) announced that Stephen F. Ghiglieri joined the Company as Executive Vice President and Chief Financial Officer, effective November 1, 2016.
Mr. Ghiglieri, age 55, has served as the Chief Financial Officer since 2013 and Chief Operating Officer since 2015 at MedData, Inc. From 2003 until 2013, he served as Executive Vice President, Chief Operating Officer and Chief Financial Officer of Neurogesx, Inc. Prior to that, he was Chief Financial Officer and Corporate Secretary at Hansen Medical, Inc. from 2002 to 2003; Executive Vice President, Chief Financial Officer and Corporate Secretary at Avolent, Inc. from 2000 to 2002; Chief Financial Officer, Vice President Finance and Corporate Secretary at Andromedia, Inc. from 1999-2000; Vice President Finance and Administration, Chief Financial Officer and Corporate Secretary at Oacis Healthcre Systems, Inc. from 1994 to 1999 and Controller at Oclassen Pharmaceuticals from 1992 to 1994. From 1984 to 1992, Mr. Ghiglieri was an Audit Manager at PricewaterhouseCoopers.
There are no family relationships between Mr. Ghiglieri and any of our directors or executive officers and there are no arrangements or understandings between his and any other persons pursuant to which he was selected as an officer. There are no related party transactions between Mr. Ghiglieri and the Company.
(e) Compensatory Arrangements.
Pursuant to the terms of an employment agreement, dated November 1, 2016, by and between the Company and Mr. Ghiglieri, effective November 1, 2016, Mr. Ghiglieri will receive an annual base salary of $370,000 and an annual incentive bonus opportunity of up to 30% of his base salary commencing in 2016 (pro-rated for 2016), to be earned based on the achievement of annual performance targets to be established by the Compensation Committee of the Board of Directors. Mr. Ghiglieri will also receive a signing bonus of $50,000 payable on the first pay date in 2017, subject to being employed on the date of payment.
On November 1, 2016, Mr. Ghiglieri was granted 1,000,000 stock options to purchase shares of common stock. Such stock options vest in sixteen (16) equal quarterly installments of 62,500 shares each over four years beginning on the first quarterly anniversary of November 1, 2016, provided, in each case, that Mr. Ghiglieri remains in the continuous employment of the Company through such quarterly anniversary dates and will become fully vested at the end of the fourth year following the grant date.
The compensation arrangements were approved by the Compensation Committee of the Board of Directors.
A copy of the press release announcing Mr. Ghiglieri's appointment as Executive Vice President and Chief Financial Officer is attached hereto as Exhibit 99.1 and incorporated herein by reference.
The foregoing description of Mr. Ghiglieri's employment agreement is qualified in its entirety by the text of the agreement, a copy of which is attached hereto as Exhibit 99.2 and incorporated herein by reference.
Item 9.01
Financial Statements and Exhibits

(d) Exhibits
99.1
Press Release of Galena Biopharma, Inc. dated November 3, 2016.
 
 
99.2
Employment Agreement between Galena Biopharma, Inc. and Stephen Ghiglieri dated November 1, 2016
 







SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
 
 
 
 
 
 
 
 
 
 
 
 
 
 
GALENA BIOPHARMA, INC.
 
 
 
 
 
 
Date:
 
November 3, 2016
 
 
 
By:
 
/s/ Mark W. Schwartz
 
 
 
 
 
 
 
 
Mark W. Schwartz Ph.D.
President and Chief Executive Officer



GALE20161103EX991IMAGE1.JPG

Galena Biopharma Appoints Stephen F. Ghiglieri as Executive Vice President and Chief Financial Officer

San Ramon, California, November 3, 2016 — Galena Biopharma, Inc. (NASDAQ: GALE), a biopharmaceutical company committed to the development and commercialization of hematology and oncology therapeutics that address unmet medical needs, today announced that Stephen F. Ghiglieri has been appointed as the Company’s Executive Vice President and Chief Financial Officer, effective immediately.

“Stephen has 30 years of senior level finance and operating experience, primarily in the life sciences industry, and has been intergral to the growth of numerous companies, from emerging stage through commercial approval and market launch,” said Mark W. Schwartz, Ph.D., President and Chief Executive Officer. “Stephen is a welcome addition to our management team as we restructure our organization and position ourselves for progressing our rich clinical pipeline. We are preparing to initiate a pivotal trial next year, and we look forward to providing a corporate update on the progress of all of our programs on our quarterly call next week.”

“I am excited to be joining Galena at this important time in the Company’s history. Galena is currently re-focusing its efforts with a backbone of valuable hematology and immunotherapy assets. I welcome the opportunity to join the team and provide guidance and leadership to help advance the company through its next stages of development. I believe we have the opportunity to build significant shareholder value by executing on a relatively lower risk clinical and regulatory development program with GALE-401 and supporting ongoing investigator and partner sponsored studies with our immunotherapy assets,” commented, Mr. Ghiglieri.

Stephen F. Ghiglieri joins Galena Biopharma with more than 30 years in senior level finance and operations roles at both biotechnology and technology companies. Prior to Galena Biopharma, Mr. Ghiglieri served as CFO of MedData Inc., a private equity backed healthcare services company that was sold to Mednax, a publicly traded national medical group.  Previously, he spent nearly 10 years at NeurogesX, ending his tenure as the Company’s Executive Vice President, Chief Operating Officer and CFO. Prior to that he served as the CFO of Hansen Medical, Inc., a medical device company. He also held senior level finance positions at two other healthcare companies: Oacis Healthcare Systems, Inc., and Oclassen Pharmaceuticals, Inc. Additionally, he was also the CFO and Corporate Secretary for two technology software companies: Avolent, Inc., and Andromedia, Inc. Mr. Ghiglieri began his career as an audit manager of PricewaterhouseCoopers, LLP. He received a Bachelor of Science in Business Administration from California State University, Hayward where he graduated Magna Cum Laude. Mr. Ghiglieri is also a Certified Public Accountant (inactive).


About Galena Biopharma

Galena Biopharma, Inc. is a biopharmaceutical company committed to the development and commercialization of hematology and oncology therapeutics that address unmet medical needs. Galena’s pipeline consists of multiple mid-to-late-stage clinical assets led by its hematology asset, GALE-401, and novel cancer immunotherapy programs including NeuVax™ (nelipepimut-S) and GALE-301/GALE-302. For more information, visit www.galenabiopharma.com .

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements include, but are not limited to, statements about the progress of the development of Galena’s product candidates, patient enrollment in our clinical trials, as well as other statements related to the progress and timing of our development activities, present or future licensing, collaborative or financing arrangements, expected outcomes with regulatory agencies, and projected market opportunities for product candidates or that otherwise relate to future periods. These forward-looking statements are subject to a number of risks, uncertainties and assumptions, including those identified under “Risk Factors” in Galena’s Annual Report on Form 10-K for the year ended December 31, 2015 and most recent Quarterly Reports on Form 10-Q filed with the SEC. Actual results may differ materially from those contemplated by these forward-looking statements. Galena does not undertake to update any of these forward-looking statements to reflect a change in its views or events or circumstances that occur after the date of this press release.

NeuVax is a trademark of Galena Biopharma, Inc.

Contact:

Remy Bernarda
SVP, Investor Relations & Corporate Communications
(925) 498-7709
ir@galenabiopharma.com

Source: Galena Biopharma, Inc.





EMPLOYMENT AGREEMENT

This Employment Agreement (this “Agreement”) is made and entered into as of November 1, 2016 (the “Effective Date”) by and between Galena Biopharma, Inc., a Delaware corporation (the “Company”, or “Employer”), and Stephen Ghiglieri, an individual and resident of the State of California (“Employee”).

BACKGROUND
Employer and Employee desire that Employee serve as the Company's Chief Financial Officer on the terms set forth in this Agreement.

AGREED TERMS
1. Engagement . Commencing on the Effective Date, Employer shall employ Employee, and Employee shall serve, as the Chief Financial Officer of the Company. Employee understands that his duties may change from time to time in the discretion of the President and Chief Executive Officer (hereinafter the “CEO”), but such duties shall be consistent with the duties customarily assigned to the Chief Financial Officer of a company substantially comparable as of the Effective Date to Employer. As a condition to the Employee's employment by the Employer, Employee and Employer shall execute the Employee Confidentiality, Non-Competition, and Proprietary Information Agreement.

2. Duties . Employee shall perform faithfully, diligently and to the best of his ability all duties assigned to him by the CEO. Employee shall perform the services contemplated under this Agreement in accordance with the policies established by the Board and under the direction of the Company's CEO. Employee shall have such corporate power and authority as shall reasonably be required to enable him to discharge his duties under this Agreement. Employee's services hereunder shall be rendered at the Company's principal executive offices, except for travel when and as required in the performance of Employee's duties hereunder.

3. Time and Efforts . Employee shall devote all of his business time, efforts, attention and energies to Employer's business and the discharge of his duties hereunder. Notwithstanding the foregoing, except as otherwise agreed to in writing, Employee shall have the right to perform such incidental services as are necessary in connection with (a) his private, passive investments, (b) charitable or community activities, (c) participation in trade or professional organizations and (d) service on the board of directors (or comparable body) of not more than one third-party entity or organization that does not compete with the Company Business (as defined in the Confidentiality Agreement), so long as the foregoing do not interfere with Employee's performance of his duties hereunder as determined in good faith by the Company.




4. Compensation . As the total consideration for Employee's services rendered under this Agreement, Employer shall pay or provide Employee the following compensation and benefits:

1. Signing Bonus . Employee shall be entitled to a one-time signing bonus (the “Signing Bonus”) of $50,000.00, payable on the first payroll date in 2017, subject to Employee being employed on the date of payment.

2. Base Salary . Employee shall be entitled to receive an annual base salary during the Term of $370,000.00 (hereinafter the "Base Salary"), payable in accordance with the usual payroll practices of Employer as established from time to time.

3. Discretionary Bonus . Employee shall be eligible to receive during each calendar year, commencing in 2016 (pro-rated for 2016), a discretionary annual target performance bonus of up to 30% of the Base Salary. The amount of any such bonus shall be determined by the Board, or the Compensation Committee of the Board, in their sole discretion.

4. Stock Option . As soon as practicable on or after the Effective Date, the Company shall grant Employee under the Company's 2016 Incentive Plan, as amended (the “Plan”), a stock option (“Option”) to purchase 1,000,000 shares of the Company's common stock. The Option shall vest in sixteen (16) equal quarterly installments of 62,500 shares each over four years beginning on the first quarterly anniversary of the Effective Date, provided, in each case, that Employee remains in the continuous employ of Employer through such quarterly anniversary date. The Option shall (a) be exercisable at an exercise price per share equal to the closing market price of the Company common stock on the date of the grant, (b) have a term of ten years, and (c) be on such other terms as shall be set forth in the Company's customary form of stock option agreement under the Plan evidencing the Option.

5. Expense Reimbursement . Employer shall reimburse Employee for reasonable business expenses incurred by Employee in connection with the performance of Employee's duties in accordance with Employer's usual practices and policies in effect from time to time. Any reimbursements hereunder shall be paid to Employee in accordance with the Company's expense reimbursement policies and procedures from time to time in effect.

6. Vacation . Employee shall be entitled to up to 20 days, prorated for any period of less than a full calendar year, of paid time off (vacation days plus sick time/personal time) for each calendar year in accordance with the Company's policies from time to time in effect, in addition to holidays observed by the Company. Paid time off may be taken at such times and intervals as the Employee shall determine, subject to the conflicting business needs of the Company, and otherwise shall be subject to the Company's policies in effect from



time to time. The number of paid time off days will accrue per pay period and will stop accruing in a calendar year once 20 days have been accrued.

7. Employee Benefits . The Company shall provide Employee and his dependents, if any, with coverage under any and all medical, dental and vision plans and other benefit programs available generally to the Company's senior executives and their dependents, to the extent Employee and his dependents satisfy the applicable eligibility requirements, and the Company shall pay, directly or indirectly, the premiums associated with any such medical plans to the same extent the Company pays such premiums for other senior executives of the Company. Employee shall be eligible to participate in any medical insurance and other employee benefits made available generally by Employer to all senior executives under Employer's plans and employment policies in effect from time to time. Employee acknowledges and agrees that any such plans or policies now or hereafter in effect may be modified or terminated by Employer at any time in its discretion.

8. Payroll Taxes . Employer shall have the right to deduct from the compensation and benefits due to Employee hereunder any and all sums required for social security and withholding taxes and for any other federal, state, or local tax or charge which may be in effect or hereafter enacted or required as a charge on the compensation or benefits of Employee.

5. Termination . This Agreement and Employee's employment may be terminated as set forth in this Section 5.

1. Termination by Employer for Cause ; Termination by Employee .
Employer may terminate Employee's employment hereunder for “Cause” (as hereinafter defined) upon notice to Employee. “Cause” for the purpose of this Agreement shall mean any of the following:

(a) Employee's breach of any material term of this Agreement, including its Exhibits; provided that the first occasion of any particular breach shall not constitute Cause unless Employee shall have previously received written notice from Employer stating the nature of such breach and affording Employee at least ten days to correct such breach;

(b) Employee s conviction of, or plea of guilty or nolo contendere to, any felony or other crime of moral turpitude;

(c) Employee’s act of fraud or dishonesty injurious to Employer or its reputation;

(d) Employee's continual failure or refusal to perform his material duties as required under this Agreement after written notice from



Employer stating the nature of such failure or refusal and affording Employee at least ten days to correct the same;

(e) Employee's act or omission that, in the reasonable determination of Employer's Board (or a Committee of the Board), indicates alcohol or drug abuse by Employee; or

(f) Employee's act or personal conduct that, in the judgment of the Board (or a Committee of the Board), gives rise to a material risk of liability of Employee or Employer under federal or applicable state law for discrimination, or sexual or other forms of harassment, or other similar liabilities to subordinate employees.

Employee may terminate his employment hereunder, for any reason or no reason, upon 30 days prior notice to Employer.

Upon termination of Employee's employment by Employer for Cause or by Employee for any reason, all compensation and benefits to Employee hereunder shall cease except that Employee shall be entitled to payment, not later than the date of termination, of (i) any accrued but unpaid salary and unused paid time off (only as accrued during the then-current year of employment), and (ii) reimbursement of business expenses accrued but unpaid as of the date of termination.

2. Termination by Employer without Cause . Employer may also terminate Employee’s employment without Cause; provided, however, that Employer shall remain obligated to continue paying in accordance with Section 4.2 Employee’s Base Salary at the time of termination for a period of six months following the termination. Upon any termination pursuant to this Section 5.2, Employee shall be entitled to payment of any unused vacation time (only as accrued as of the date of such termination as provided in this Agreement and in accordance with applicable law) and reimbursement of business expenses accrued but unpaid as of the date of termination. If during the Term, there is a Change of Control of Employer and (i) the Employee is terminated without Cause, (ii) the compensation, benefits, title, or duties of Employee under this Agreement are significantly reduced, or (iii) Employee must relocate more than 50 miles from his current residence, Employee shall be considered terminated by Employer without Cause and Employer or any successor to Employer shall remain obligated to continue paying in accordance with Section 4.2 Employee’s Base Salary at the time of termination for a period of twelve months following the date of termination, with all of the benefits and payments due Employee as detailed in this Section 5.2. Change of Control shall mean any of the following transactions, provided, however, that the Company shall determine whether multiple or successive transactions are related to constitute a Change in Control, and its determination shall be final, binding and conclusive: (1) any “person” (as such term is used in Sections 13(d) and 14(d) of the Exchange Act) becomes the “beneficial owner” (as defined in Rule 13d-3 of the Exchange Act), directly or



indirectly, of securities of the Company representing 50% or more of the total voting power represented by the Company's then outstanding voting securities; (2) the consummation of the sale, liquidation or disposition by the Company of all or substantially all of the Company's assets; or (3) the consummation of a merger, consolidation, reorganization or other corporation transaction involving the Company, in each case, in which the voting securities of the Company outstanding immediately prior thereto do not continue to represent (either by remaining outstanding or by being converted into voting securities of the surviving entity or its parent) at least 50% of the total voting power represented by the voting securities of the Company or such surviving entity or its parent outstanding immediately after such transaction.

3. Death or Disability . Employee's employment will terminate automatically in the event of Employee's death or upon notice from Employer in event of Employee's permanent disability. Employee's “permanent disability” shall have the meaning ascribed to such term in any policy of disability insurance maintained by Employer (or Employee, as the case may be) with respect to Employee, or if no such policy is then in effect , shall mean Employee's inability to fully perform his duties hereunder with or without reasonable accommodation for any period of at least ninety (90) consecutive days, or for a total of one hundred twenty (120) days, whether or not consecutive, within any period of one hundred eighty (180) consecutive days. Upon termination of Employee ' s employment as aforesaid, all compensation and benefits to Employee hereunder shall cease and Employee, or Employee's heirs or personal representatives, as applicable, shall be entitled to the same compensation and benefits as provided in Section 5.1 for termination by Employer for Cause.

6. Indemnification; Insurance .

1. Indemnification . In the event that Employee is made a party or threatened to be made a party to any action, suit, or proceeding, whether civil, criminal, administrative or investigative (a “Proceeding”), other than any Proceeding initiated by Employee or the Company related to any contest or dispute between Employee and the Company or any of its affiliates with respect to this Agreement or Employee 's employment hereunder , by reason of the fact that the Employee is or was a director or officer of the Company , or any affiliate of the Company, or is or was serving at the request of the Company as a director, officer, member, employee or agent of another corporation or a partnership, joint venture, trust or other enterprise, Employee shall be indemnified and held harmless by the Company to the fullest extent permitted under applicable law and the Company's bylaws from and against any liabilities, costs, claims and expenses, including all costs and expenses incurred in defense of any Proceeding (including reasonable attorneys' fees). Costs and expenses incurred by Employee in defense of such Proceeding (including attorneys' fees) shall be paid by the Company in advance of the final disposition of such litigation upon



receipt by the Company of: (i) a written request for payment; (ii) appropriate documentation evidencing the incurrence, amount and nature of the costs and expenses for which payment is being sought; and (iii) an undertaking adequate under applicable law made by or on behalf of Employee to repay the amounts so paid if it shall ultimately be determined that Employee is not entitled to be indemnified by the Company under this Agreement.

2. Insurance . During the Employment term, the Company shall purchase and maintain, at its own expense, directors' and officers' liability insurance providing coverage to Employee on terms that are no less favorable than the coverage provided to other directors and similarly situated executives of the Company.

7. Clawback Provisions . Notwithstanding any other provisions in this Agreement to the contrary, any incentive-based compensation, or any other compensation, paid to Employee pursuant to this Agreement or any other agreement or arrangement with the Company which is or may become subject to recovery under any law, government regulation or stock exchange listing requirement, will be subject to such deductions and clawback as may be required to be made pursuant to such law, government regulation or stock exchange listing requirement (or any policy adopted by the Company pursuant to any such law, government regulation or stock exchange listing requirement). The Company will make any determination for clawback or recovery in its sole discretion and in accordance with any applicable law or regulation.

8. Severable Provisions . The provisions of this Agreement are severable and if any one or more provisions is determined to be illegal or otherwise unenforceable, in whole or in part, the remaining provisions, and any partially unenforceable provisions to the extent enforceable, shall nevertheless be binding and enforceable.

9. Successors and Assigns . This Agreement shall inure to the benefit of and shall be binding upon and enforceable by the parties and their respective successors, assigns, heirs and representatives; provided, however, that neither party may assign this Agreement without the prior written consent of the other party; and, provided further, that this Agreement may be assigned by the Company to a successor (whether direct or indirect, by purchase, merger, consolidation or otherwise) to all or substantially all of the business or assets of Employer.

10. Entire Agreement . This Agreement, including the Confidentiality Agreement, contains the entire agreement of the parties relating to the subject matter hereof, and the parties hereto have made no agreements, representations or warranties relating to the subject matter of this Agreement that are not set forth otherwise therein or herein. Except as expressly provided herein, this



Agreement (including the Confidentiality Agreement) supersedes any and all prior or contemporaneous agreements, written or oral, between Employee and Employer relating to the subject matter hereof.

11. Amendment . No modification of this Agreement shall be valid unless made in writing, approved by the Board (or a committee of the Board) and signed by the parties hereto. The parties hereto agree that in no event shall an oral modification of this Agreement be enforceable or valid.

12.
Governing Law; Arbitration .

1. Governing Law . This Agreement is and shall be governed and construed in accordance with the laws of the State of California without giving effect to the choice-of-law rules of California.

2.
Employer and Employee agree that arbitration pursuant to this
Section 12.2 shall be the sole and exclusive method for resolving any claim or dispute arising out of or relating to the rights and obligations of the Company and Employee pursuant to this Agreement. Employer and Employee shall mutually agree on the arbitrator; provided, however , that if Employer and Employee cannot mutually agree on the arbitrator, either Employer or Employee can request that JAMS, Inc. (“JAMS”) select the arbitrator. The arbitrator shall have at least ten (10) years' experience with respect to employment matters. Any such arbitration shall be held in San Francisco, California, under JAMS's Employment Arbitration Rules & Procedures (the “JAMS Rules & Procedures”) then in effect. A copy of the current JAMS Rules & Procedures is attached hereto as Exhibit A. The JAMS Rules & Procedures are also available online at www.jamsadr.com/rules-employment arbitration . The arbitrator shall set a limited time period and establish procedures designed to reduce the cost and time for discovery while allowing Employer and Employee an opportunity, adequate in the sole judgment of the arbitrator, to discover relevant information from the opposing parties about the subject matter of the dispute. The arbitrator shall rule upon motions to compel or limit discovery and shall have the authority to impose sanctions, including attorneys' fees and costs, to the same extent as a court of law or equity, should the arbitrator determine that discovery was sought without substantial justification or that discovery was refused or objected to without substantial justification. The decision of the arbitrator shall be written, shall be in accordance with applicable law, and shall be supported by written findings of fact and conclusions of law, which shall set forth the basis for the decision of the arbitrator. The arbitrator shall render a written decision on the claim or dispute presented as soon as practicable and in any event not more than forty-five (45) days after the close of evidence and briefing. The decision of the arbitrator as to the validity and amount of any claim disputed by Employer and Employee shall be binding and conclusive upon such parties to this Agreement, and notwithstanding anything in this Section 12.2, such parties shall be required to act in accordance with such decision. Judgment upon any award rendered by the arbitrator may be entered in any court having jurisdiction. Employer will pay all costs of the arbitration, including administrative and arbitrator fees, other than costs the parties



would normally incur in a civil action. In the event that a judgment is made pursuant to this Section 12.2, all reasonable out of pocket costs and reasonable legal costs incurred by the prevailing party shall be paid by the non-prevailing party. Any decision , judgment, ruling, finding, award or other determination of the arbitrator and any information disclosed in the course of any arbitration hereunder shall be kept confidential by Employer and Employee, and any court order to enforce the decision, judgment, ruling, finding, award or other determination of the arbitrator shall be filed under seal. This agreement to arbitrate is freely negotiated between Employee and Employer and is mutually entered into between the parties. Each party fully understands and agrees that they are giving up certain rights otherwise afforded them by civil court actions, including, but not limited to, the right to a jury trial.

______By initialing here, Employee acknowledges he has read this 12.2 and agrees with the arbitration provisions herein.

13. Notice . All notices and other communications under this Agreement shall be in writing and mailed, electronically mailed, telecopied (in case of notice to Employer only) or delivered by hand or by a nationally recognized courier service guaranteeing overnight delivery to a party at the following address (or to such other address as such party may have specified by notice given to the other party pursuant to the provision):

If to Employer:

Galena Biopharma, Inc.
Attention: Chief Executive Officer 2000 Crow Canyon Place, Suite 380 San Ramon, California 95483 Phone: 855-855-4253

If to Employee:

Through the Company e-mail or the Company regular mailbox, if utilized by the Company, or if Employee shall no longer be employed, to Employee's address as reflected in the books and records of Employer.

14. Survival . Sections 6 through 13 and Section 16 shall survive the termination of this Agreement.

15. Counterparts . This Agreement may be executed in counterparts, each of which shall be deemed to be an original and all of which together shall be deemed to be one and the same agreement. Each party may sign this Agreement using an electronic or handwritten signature, whether on an original or an electronic counterpart of this Agreement.




16. Attorney's Fees . In any action or proceeding to construe or enforce any provision of this Agreement the prevailing party shall be entitled to recover its or his reasonable attorneys' fees and other costs of suit in addition to any other recoveries.

[Signature Page Follows]





By signing below, each party acknowledges that it or he has read and understands this Agreement, and each party agrees to be bound by the terms of this Agreement.

EMPLOYER

Galena Biopharma, Inc.

By: /s/ Mark W. Schwartz
                
Mark W. Schwartz, Ph.D.
President and Chief Executive Officer


EMPLOYEE

By: /s/ Stephen Ghiglieri                 
Stephen Ghiglieri